The R&D facility in Medford, located just north of Cambridge (MA) allows Batavia Biosciences to extend the existing service portfolio in the US, adding complete pre-clinical process development capabilities for viral vectors including AAV, Lentivirus, VSV and Adenovirus systems to its portfolio of CHO cell line generation and process development services for recombinant proteins and antibodies.
Chris Yallop, CSO Batavia Biosciences, said: “Recent advances in cancer vaccines and gene therapy have given rise to a profound increase in the global demand for process development and clinical manufacturing of vector based products.”
In addition expansion of its GMP cleanroom facilities in Leiden, the Netherlands better aligns the company’s GMP capacity with its increased R&D capability to further support the manufacturing of master cell banks and vaccine seed stocks.
Menzo Havenga, CEO Batavia Biosciences, said: “At Batavia Biosciences we are very much aware of the fact that the patient is waiting. With the completion of this investment, the company is now better positioned to maintain the speed and quality of bringing candidate biopharmaceuticals from bench to clinic.”
